Armata Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• Armata Pharmaceuticals (ARMP) announced and furnished a press release reporting its financial results for the three and six months ended June 30, 2026. The 8‑K was filed and dated August 12, 2026, and the press release is attached as Exhibit 99.1.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting periods: three and six months ended June 30, 2026.
• Exhibit included: 99.1 — Press Release dated August 12, 2026 (and Exhibit 104 interactive XBRL cover page).
• Report signed on behalf of the company by David House, Chief Financial Officer (Principal Financial Officer).

Why It Matters

• This 8‑K makes Armata’s latest quarterly financial results public, which investors use to assess revenue, expenses, cash position and progress against company goals.
• Because the filing references a press release (Exhibit 99.1) for the details, investors should review that release or the company’s quarterly filings for the specific financial figures and any management commentary on performance or guidance.
• No other material events (e.g., executive changes, mergers, bankruptcies) were reported in this filing.